Study supports illegal darbepoetin marketing claim

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Use of erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA) decreased between 2002 and 2010. 
  • Per-patient dosing of darbepoetin (Aranesp), but not epoetin (Mircera), increased between 2003 and 2010. 
  • Monthly per-patient costs decreased 3% for epoetin and incr...